Journal
ONCOLOGY REVIEWS
Volume 14, Issue 2, Pages 135-143Publisher
PAGEPRESS PUBL
DOI: 10.4081/oncol.2020.490
Keywords
Immune-checkpoint inhibitor; PD1; PD-L1; lung cancer; immune-related adverse events
Categories
Funding
- Roche
- Pfizer
- Seqirus
- AstraZeneca
- Novartis
- Bristol-Myers Squibb
- Sanofi
- Istituto Gentili
- Ipsen
- Boehringer-Ingelheim
Ask authors/readers for more resources
Anti-PD1 and anti-PD-L1 agents may have intrinsic and clinically relevant differences in the treatment of non-small cell lung cancer (NSCLC) patients. By reviewing currently available indirect evidence on these agents for NSCLC treatment, highlighting possible inter- and intra-class dissimilarities, anti-PD1 agents showed a higher response rate and a better outcome when combined with chemotherapy for the first-line treatment of patients with squamous and PD-L1 low advanced NSCLC, as compared to anti-PD-L1 agents. Conversely, anti-PD-L1 agents were responsible for less severe adverse events (AEs), particularly, immune-related AEs. These differences could be explained by their different specific properties. Considering possible differences between anti-PD1 and anti-PD-L1 agents could be clinically relevant for treatment tailoring and inspiring new investigational approaches.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available